Semaglutide is a revolutionary medical treatment designed to combat obesity and aid in weight loss. It is a small protein (peptide) that works by activating metabolic pathways in the body, effectively increasing blood sugar metabolism and reducing appetite. This remarkable medication mimics the action of glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in regulating blood sugar levels and managing body weight.

Choosing Semaglutide for your medical weight loss journey can significantly improve your quality of life in various ways. Some of the key benefits of this treatment include:

• Substantial and sustainable weight loss
• Reduced appetite and increased feeling of fullness
• Targeted fat-burning, preserving muscle mass
• Improved blood sugar regulation
• Prevention of plaque buildup in blood vessels
• Enhanced insulin pathways and blood sugar levels
• Boosted energy levels and overall well-being
• Unlike surgical weight loss procedures, this treatment offers a non-invasive option with minimal downtime. This means you can continue with your daily activities while undergoing treatment without the need for lengthy recovery periods.

If you have been struggling to lose weight through traditional diet and exercise alone, Semaglutide may be the solution you’ve been looking for. However, not everyone is a suitable candidate for this treatment.

It is essential to discuss your medical history, allergies, and any existing health conditions with our experienced medical team to determine if this treatment is the right fit for you. Generally, individuals with a history or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or type 1 diabetes are not eligible for treatment.

To determine if you’d make a good candidate for Semaglutide at Le Lux Beautique Med Spa can address that and answer any questions you may have during a consultation. Call us today!

• What are the signs that you need medically supervised weight loss?

  Signs that you may need medically supervised weight loss include:

  • Difficulty losing weight despite numerous attempts.
  • A body mass index (BMI) that classifies as obese.
  • Weight-related health issues such as diabetes, high blood pressure, or sleep apnea.
  • Rapid weight gain without a clear cause.
  • Excessive hunger or inability to feel full.
  • Emotional eating or dependency on food for comfort.

  These symptoms typically signal difficulties in managing weight through conventional methods alone. Patients with significant weight concerns may also find a structured, medical approach to treat obesity beneficial. If you identify with these signs, a medically supervised program could provide an effective solution. Arrange a professional consultation to assess whether this treatment program is suitable for your needs.

• Does Semaglutide really work?

  Yes, this treatment has shown remarkable effectiveness in aiding weight loss and improving metabolic processes in the body.
• Is Semaglutide safe?

  Semaglutide is generally safe for eligible candidates. However, like any medical treatment, it may have some side effects. Our medical team will assess your suitability for the treatment and address any concerns you may have.
• Is Semaglutide a long-term solution for weight loss?

  Semaglutide can be a long-term solution for weight loss, provided it is accompanied by a healthy lifestyle and dietary changes.
• Are there any effective over-the-counter alternatives to Semaglutide out there?

  While there are some over-the-counter weight loss products available, none have demonstrated the effectiveness and safety profile of Semaglutide.
• How much does Semaglutide cost?

  The cost of Semaglutide treatment may vary based on individual needs. During your consultation, we will provide you with a detailed breakdown of the costs involved and discuss available payment options.

Medullary Thyroid Carcinoma (MTC) and Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2) 

Like other GLP-1RA medications, semaglutide has a boxed warning of a risk of thyroid c-cell tumors and is contraindicated in people with a personal or family history of MTC or in patients with MEN 2. This warning is based on data from rodents demonstrating that semaglutide causes dose- and treatment duration-dependent thyroid C-cell tumors.62 In rodents, thyroid C-cells highly express the GLP-1 receptor.62 GLP-1 receptor agonists stimulate upregulation of the calcitonin gene expression, calcitonin release, C-cell hyperplasia, and increased risk of medullary adenomas and carcinomas in rodents.62 However, these findings have not been found in nonhuman primates or in humans, which has been attributed to the very low thyroid C-cell density and GLP-1 receptor expression in thyroids of humans relative to rodents.62,63 Serum calcitonin at concentrations ≥100 ng/L is highly specific as a tumor marker for neoplasia of the thyroid C-cells, with lower concentrations having lower specificity.64 Among participants in the STEP 1 study, there was no significant difference between semaglutide and placebo-treated participants in change from baseline to 68 weeks in calcitonin levels.21 In a meta-analysis of 11 trials, there was no increase in the risk of thyroid disorders in participants treated with semaglutide relative to placebo (RR = 0.75; 95% CI = 0.35, 1.57).65 However, these events are rare, and people at individual or familial risk for MTC and MEN 2 and those with high baseline calcitonin were excluded from the STEP trials. In addition, most studies have been of relatively short duration. The rarity and long-term timeline of these events require larger-scale, longer-duration, randomized clinical trials designed to assess the effects of semaglutide on the thyroid system. Patients should be informed that it is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma in humans.

Hypersensitivity 

A known hypersensitivity to semaglutide or any of its excipients is a contraindication for use of the medication. Caution also should be used in patients with a history of hypersensitivity to other GLP-1RAs. GLP-1RAs, including semaglutide, are protein-based molecules and are thus potentially immunogenic.23,66 Antibodies can increase risk of local or systemic hypersensitivity. However, the clinical significance of anti-semaglutide antibodies appears to be low in most people. For example, in the STEP 6 trial, 2% of participants on semaglutide 2.4 mg developed anti-drug antibodies, and these were all cross-reactions with endogenous GLP-1 with no occurrences of anti-drug neutralized antibodies or anti-drug antibodies with endogenous GLP-1 neutralizing effects.50 Rare but serious hypersensitivities including anaphylaxis and angioedema have been reported. Patients should seek medical treatment and discontinue the medication if they develop a serious hypersensitivity.

Pregnancy 

Data from animal studies suggest that GLP-1RAs should not be used in pregnancy due to potential risks of embryofetal mortality, structural abnormalities, and alterations to growth.61 There is insufficient human data to evaluate semaglutide for use in pregnancy. Pregnancy is a contraindication for use of semaglutide, and semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life.